Krystal Biotech

KRYS

311.5002.70% ( -8.630 )

Closed: Oct 23, 16:00:00 (EDT)

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line but beat significantly on profitability: revenue of $119.2M vs. $121.0M expected, while GAAP EPS reached $1.79, exceeding the $1.63 mean estimate. Strong gross margins of 95.0% (in-line) and efficient manufacturing helped drive an EBIT of $58.4M, 6.38% above consensus. While U.S. sales declined, international launches in Europe and Japan provided a critical growth offset, contributing $27.6M to the quarter.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Krystal Biotech(KRYS) the Revenue is 119.22 M (+24.14%), Miss estimate;the EBIT is 58.42 M (+48.62%), Beat estimate;the EPS is 1.79 (+38.76%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueMiss expectations

0.12B24.14%

0.12B26.03%

-0.00B1.89%

EBITExceed expectations

0.06B48.62%

0.05B39.70%

+0.00B8.92%

EPSExceed expectations

1.7938.76%

1.627526.16%

+0.162512.60%

Upcoming earnings report - Q3 FY2026

Available dateNov 2, 2026

Estimate Revenue$126.54 M

Estimate EBIT$58.48 M

Estimate EPS$1.7711

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly